These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 26761967)

  • 21. The role of nicorandil in the treatment of myocardial ischaemia.
    Falase B; Easaw J; Youhana A
    Expert Opin Pharmacother; 2001 May; 2(5):845-56. PubMed ID: 11336627
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Determinants of coronary events in patients with stable angina: results from the impact of nicorandil in angina study.
    IONA Study Group
    Am Heart J; 2005 Oct; 150(4):689. PubMed ID: 16209965
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety profile of an anti-anginal agent with potassium channel opening activity: an overview.
    Roland E
    Eur Heart J; 1993 Jul; 14 Suppl B():48-52. PubMed ID: 8370373
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nicorandil: a review of its use in the management of stable angina pectoris, including high-risk patients.
    Simpson D; Wellington K
    Drugs; 2004; 64(17):1941-55. PubMed ID: 15329045
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nicorandil. A review of its pharmacology and therapeutic efficacy in angina pectoris.
    Frampton J; Buckley MM; Fitton A
    Drugs; 1992 Oct; 44(4):625-55. PubMed ID: 1281076
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of intravenous nicorandil and preexisting angina pectoris on short- and long-term outcomes in patients with a first ST-segment elevation acute myocardial infarction.
    Ishii H; Ichimiya S; Kanashiro M; Amano T; Ogawa Y; Mitsuhashi H; Sakai S; Uetani T; Murakami R; Naruse K; Murohara T; Matsubara T
    Am J Cardiol; 2007 May; 99(9):1203-7. PubMed ID: 17478142
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Nicorandil in the treatment of patients with ischemic heart disease].
    Minushkina LO; Sidorenko BA
    Kardiologiia; 2013; 53(5):69-73. PubMed ID: 23952998
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bevacizumab-Related Microvascular Angina and Its Management with Nicorandil.
    Katoh M; Takeda N; Arimoto T; Abe H; Oda K; Osuga Y; Fujii T; Komuro I
    Int Heart J; 2017 Oct; 58(5):803-805. PubMed ID: 28966326
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potassium channel openers in myocardial ischaemia: therapeutic potential of nicorandil.
    Gomma AH; Purcell HJ; Fox KM
    Drugs; 2001; 61(12):1705-10. PubMed ID: 11693460
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of nicorandil in angina: subgroup analyses.
    IONA Study Group
    Heart; 2004 Dec; 90(12):1427-30. PubMed ID: 15547020
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Attenuation of anti-ischemic efficacy during chronic therapy with nicorandil in patients with stable angina pectoris.
    Rajaratnam R; Brieger DB; Hawkins R; Freedman SB
    Am J Cardiol; 1999 Apr; 83(7):1120-4, A9. PubMed ID: 10190531
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Thiotriazoline in the Treatment of Stable Angina Pectoris of II-III Functional Class].
    Kadin DV; Chumak BA; Filippov AE; Shustov SB
    Kardiologiia; 2015; 55(8):26-9. PubMed ID: 26761968
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term administration of nicorandil abolishes ischemic and pharmacologic preconditioning of the human myocardium: role of mitochondrial adenosine triphosphate-dependent potassium channels.
    Loubani M; Galiñanes M
    J Thorac Cardiovasc Surg; 2002 Oct; 124(4):750-7. PubMed ID: 12324733
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Comparative Assessment of Effects of Isosorbide Dinitrate, Isosorbide-5-Mononitrate and Nicorandil on the Frequency of Angina Attacks and Vasoregulating Endothelial Function in Patients With Ischemic Heart Disease].
    Sizova ZM; Kozlova NV; Zakharova VL; Shameeva ES
    Kardiologiia; 2015; 55(2):10-5. PubMed ID: 26164982
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Economic evaluation of the impact of nicorandil in angina (IONA) trial.
    Walker A; McMurray J; Stewart S; Berger W; McMahon AD; Dargie H; Fox K; Hillis S; Henderson NJ; Ford I
    Heart; 2006 May; 92(5):619-24. PubMed ID: 16614274
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Systematic review on the short-term efficacy and safety of nicorandil for stable angina pectoris in comparison with those of β-blockers, nitrates and calcium antagonists].
    Hanai Y; Mita M; Hishinuma S; Shoji M
    Yakugaku Zasshi; 2010 Nov; 130(11):1549-63. PubMed ID: 21048416
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potassium channel activators in vasospastic angina.
    Lablanche JM; Bauters C; McFadden EP; Quandalle P; Bertrand ME
    Eur Heart J; 1993 Jul; 14 Suppl B():22-4. PubMed ID: 8370368
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relative efficacy of antianginal drugs used as add-on therapy in patients with stable angina: A systematic review and meta-analysis.
    Belsey J; Savelieva I; Mugelli A; Camm AJ
    Eur J Prev Cardiol; 2015 Jul; 22(7):837-48. PubMed ID: 24776376
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Trial to show the impact of nicorandil in angina (IONA): design, methodology, and management.
    IONA Study Group
    Heart; 2001 Jun; 85(6):E9. PubMed ID: 11359763
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antianginal and anti-ischemic efficacy of nicorandil compared with nifedipine in patients with angina pectoris and coronary heart disease: a double-blind, randomized, multicenter study.
    Ulvenstam G; Diderholm E; Frithz G; Gudbrandsson T; Hedbäck B; Höglund C; Moelstad P; Perk J; Sverrisson JT
    J Cardiovasc Pharmacol; 1992; 20 Suppl 3():S67-73. PubMed ID: 1282179
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.